Boyds has announced the launch of a brand-new podcast series that aims to keep the scientific and clinical community abreast of the latest advancements in cell and gene therapy and drug development.
The podcast – ‘Conversations in Drug Development’ – features candid conversations from the expert team at Boyds, who are at the forefront of cutting-edge drug development in the pharmaceutical and biotechnology sector.
Commenting on the podcast, Professor Alan Boyd, President and CEO of Boyds, says: “I am incredibly excited about the launch of Conversations in Drug Development. In this series, Boyds’ experts and special guests will share their stories, experiences, and expertise, offering a behind-the-scenes look at the cutting-edge research, clinical trials, regulatory hurdles, and numerous other factors that shape the drug development landscape.
“Whether you’re a healthcare professional, a patient, a researcher, or simply curious about the world of medicine, this podcast promises to expand your understanding of the complex journey from molecule to medicine. We hope fellow scientists will join us in exploring this dynamic and ever-evolving field.”
In the first episode of Conversations in Drug Development, Dr Katherine Bowen and Dr Julie Warner delve deep into the ever-evolving world of oncology drug development and the regulatory landscape in the US and EU.
In the second episode, Dr Julie Warner and Harriet Edwards discuss the revolutionising role of artificial intelligence (AI) in drug development, exploring its applications in data analysis and toxicity prediction, and its potential to reduce animal testing.
Listen and subscribe to Conversations in Drug Development here.
